New-Onset Type 1 Diabetes Mellitus After Treatment With Nivolumab for Melanoma

Sarah Baroud; Lubna Mirza

doi:10.7759/cureus.18679

New-Onset Type 1 Diabetes Mellitus After Treatment With Nivolumab for Melanoma

Cureus. 2021 Oct 11;13(10):e18679. doi: 10.7759/cureus.18679. eCollection 2021 Oct.

Authors

Sarah Baroud¹, Lubna Mirza²

Affiliations

¹ Department of Internal Medicine, Sheikh Khalifa Medical City, Abu Dhabi, ARE.
² Department of Endocrinology, Norman Regional Health System, Norman, USA.

Abstract

A 67-year-old female taking Nivolumab for melanoma developed a hyperglycemic emergency requiring hospital admission. She was referred to our endocrinology clinic post-discharge where she was diagnosed with new-onset Type 1 diabetes mellitus. Severe hyperglycemia and immune-mediated diabetes mellitus are extremely rare but potentially life-threatening side effects of Nivolumab.

Keywords: hyperglycemia; immunotherapy; melanoma; nivolumab; type 1 diabetes.

Publication types

Case Reports